Arvinas Says It Presented New Preclinical Data From Its Investigational BCL6 PROTAC Degrader ARV-393, Company Also Disclosed New Preclinical Data From PROTAC LRRK2 Degrader Program
Portfolio Pulse from Benzinga Newsdesk
Arvinas presented new preclinical data for its investigational BCL6 PROTAC degrader ARV-393, showing anti-tumor activity in B-cell lymphoma models. The data suggest potential for ARV-393 as a treatment for non-Hodgkin lymphoma.
June 21, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arvinas presented new preclinical data for ARV-393, showing significant anti-tumor activity in B-cell lymphoma models. This suggests potential for ARV-393 as a new treatment for non-Hodgkin lymphoma, which could positively impact the company's future revenues.
The presentation of promising preclinical data for ARV-393 indicates potential for a new treatment for non-Hodgkin lymphoma. This could lead to future clinical trials and, if successful, eventual market approval, positively impacting Arvinas' revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100